This pharma stock hits all-time high, surges over 20% in a month amid weak market

The stock rose as much as 1.81% to ₹31,750 per share on the National Stock Exchange to hit an all-time high. At 11:05 am, it was up 1.25% to ₹3,1,574 apiece.

In the past month, the scrip has gained 20.49%, while it has surged 6% year-to-date. In the past year, it has advanced 12.27%.

Abbott India is a constituent of the NIFTY Pharma index, which is down 0.44%, dragged by Sun Pharma, Alkem Laboratories and Aurobindo Pharma.

From the NIFTY pack, Bajaj Auto, Bajaj Finserv, Hero MotoCorp, Nestle India and Titan were among the laggards.

State Bank of India, Bharat Electronics, Trent, Bharat Petroleum Corporation Ltd and Tata Consultancy Services were the gainers.

United States President Donald Trump said on Monday that 25% taxes on imports from Canada and Mexico will take shape on Tuesday, sparking renewed fears of a global trade war. Further, an additional 10% tariff is being imposed on China.

Abbott India Q3 results

Abbott India reported a 12.32% increase in its revenue from operations to ₹1,614.28 crore in the third quarter of the financial year 2024-25. The revenue was ₹1,437.14 crore in the corresponding period last fiscal.

Profit after tax (PAT) ascended 16% to ₹360.78 crore in the latest October-December quarter, compared to ₹310.98 crore in the year-ago quarter.

Earnings before interest, taxes, depreciation, and amortisation stood at ₹436.2 crore in the reporting quarter, reflecting an increase of 12.5% from ₹387.7 crore in Q3 FY24. Margins stayed steady at 27%.